Skip to content
An Initiative of AVAC
Search
Back to Events Archive

HIV Prevention Re-mix: Current tools, new tools, same goal

Wednesday24September
Virtual

Join the UNITED! Movement and AVAC to learn more about the future of HIV prevention and what this means for young people. The webinar will cover:

  • Prevention options currently available
  • Long-acting PrEP products, including those currently available, available soon, and in the pipeline
  • An update on the introduction of six month lenacapavir for PrEP
  • Advocacy priorities for long-acting PrEP research and rollout, with a focus on what these mean for youth
  • Experiences from youth advocates involved with PrEP introduction and rollout

The session will also include time for Q&A with speakers.

Topic(s): Community/Advocacy, Research, Service Delivery

Product(s): Cabotegravir, Dapivirine Vaginal Ring, Injectable Prep, Lenacapavir, MK-8527, Oral PrEP

Population(s): Adolescent Girls and Young Women, Adolescents and Young People

Source(s): UNITED! Movement/AVAC

Featured Resources

External Link

Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

This article from AIDS and Behavior explores preferences for various long-acting PrEP modalities amongst pregnant and lactating people in Botswana and South Africa. It further examines participants’ HIV risk perception during pregnancy and breastfeeding, their perceived individual-level facilitators and barriers of each PrEP modality, and the support needed by participants for PrEP uptake and continuation.
External Link

Global Forecast of Long-Acting PrEP Need for Key Populations (2025–2030)

Developed by AVAC, Avenir, and Global Black Gay Men Connect, this first-of-its-kind forecast estimates: 11.16 million person-years of PrEP needed annually by 2030 among men who have sex with men, transgender women, female sex workers, and people who inject drugs Uptake scenarios for cabotegravir, lenacapavir, and oral monthly PrEP Forecasts segmented by region, population group,…
Document

Standard Operating Procedure for Injectable Lenacapavir as Pre-exposure Prophylaxis

This document, developed by the South to South Learning Network, provides an adaptable standard operating procedure (SOP) to support the development and adoption of national SOPs that align with World Health Organization recommendations and guidance on injectable lenacapavir for PrEP. Click here for a version of this resource in Word format.
External Link

The WHO and Jhpiego Provider Training Toolkit on Use of Oral and Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

This toolkit is designed to help clinicians develop knowledge and skills to provide multiple HIV PrEP methods. The toolkit includes resources for oral PrEP, long-acting cabotegravir (CAB-LA), dapivirine vaginal ring (DVR), and long-acting lenacapavir (LEN). Click here to download the full set of additional resources for this training.
External Link

Long-Acting PrEP Market Assessment for Key Populations: Global access and readiness report (2025)

This market assessment supports countries, donors, implementing partners, and advocates in making informed decisions about the introduction, scale-up, and equitable delivery of long-acting PrEP among key populations and other priority groups.
External Link

Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis

In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic…
External Link

Expanding Access to a Choice-Based HIV Prevention Market

This special JIAS supplement illustrates current evidence, implementation learnings and challenges associated with the introduction, uptake, and continued use of PrEP within the context of an expanded HIV prevention method-mix.
Document

Lessons from the Field: ​​Getting PrEP Rollout Right This Time

Thirteen years after oral PrEP’s introduction, global uptake remains slow, with just over 9 million initiations—falling short of UNAIDS’ 2025 targets. While HIV infections are declining in some regions, others are experiencing increasing epidemics. Despite challenges, lessons from oral PrEP and CAB rollout have strengthened health systems for scaling up longer-acting PrEP. AVAC undertook a…
Presentation

Dapivirine Vaginal Ring Early Market Access Vehicle (EMAV)

In response to the voices of adolescent girls and women who need more HIV prevention choices, The Global Fund (GF) and the Children Investment Fund Foundation (CIFF) have partnered to make dapivirine vaginal rings available in GF-supported countries through an early market access vehicle. See here for EMAV request form in English. For guidance on…
External Link

A Mixed-Method Study of Feasibility and Acceptability of the Dapivirine Vaginal Ring among Adolescent Girls and Young Women (AGYW) in Selected Zimbabwean Districts

This article from PLOS Global Public Health describes the results of a study assessing the acceptability and feasibility of introducing the dapivirine vaginal ring (DVR) as an HIV prevention method among young women in Zimbabwe and to assess motivations and barriers of DVR uptake among the target population.